Page 45 - IJB-9-6

International Journal of Bioprinting Transdermal delivery of printed cisplatin

Animal Experiments and the Greek Ministry of Agriculture 10. Vikas P, Borcherding N, Chennamadhavuni A, et al., 2020,
(Protocol #1392861, 28/12/22). Therapeutic potential of combining PARP inhibitor and
immunotherapy in solid tumors. Front Oncol, 10(April): 570.
Consent for publication https://doi.org/10.3389/fonc.2020.00570
Not applicable. 11. Klinakis A, Karagiannis D, Rampias T, 2020, Targeting DNA
repair in cancer: Current state and novel approaches. Cell
Availability of data Mol Life Sci, 77(4): 677–703.
Data available on request. https://doi.org/10.1007/s00018-019-03299-8
12. Balmana J, Tung NM, Isakoff SJ, et al., 2014, Phase I trial
References of olaparib in combination with cisplatin for the treatment
of patients with advanced breast, ovarian and other solid
1. Tsimberidou AM, Fountzilas E, Nikanjam M, et al., 2020, tumors. Ann Oncol, 25(8): 1656–1663.
Review of precision cancer medicine: Evolution of the
treatment paradigm. Cancer Treat Rev, 86(June): 102019. https://doi.org/10.1093/annonc/mdu187
https://doi.org/10.1016/j.ctrv.2020.102019 13. Fong PC, Boss DS, Yap TA, et al., 2009, Inhibition of
poly(ADP-ribose) polymerase in tumors from BRCA
2. Zhong L, Li Y, Xiong L, et al., 2021, Small molecules in mutation carriers. N Engl J Med, 361(2): 123–134.
targeted cancer therapy: Advances, challenges, and future
perspectives. Signal Transduct Target Ther, 6(1): 201. https://doi.org/10.1056/NEJMoa0900212
https://doi.org/10.1038/s41392-021-00572-w 14. Audeh MW, Carmichael J, Penson RT, et al., 2010, Oral
poly(ADP-ribose) polymerase inhibitor olaparib in patients
3. Lord CJ, Ashworth A, 2017, PARP inhibitors: Synthetic with BRCA1 or BRCA2 mutations and recurrent ovarian
lethality in the clinic. Science, 355(6330): 1152–1158. cancer: A proof-of-concept trial. Lancet, 376(9737):
https://doi.org/10.1126/science.aam7344 245–251.
4. Ray Chaudhuri A, Nussenzweig A, 2017, The multifaceted https://doi.org/10.1016/S0140-6736(10)60893-8
roles of PARP1 in DNA repair and chromatin remodelling. 15. Tutt A, Robson M, Garber JE, et al., 2010, Oral poly(ADP-
Nat Rev Mol Cell Biol, 18(10): 610–621.
ribose) polymerase inhibitor olaparib in patients with
https://doi.org/10.1038/nrm.2017.53 BRCA1 or BRCA2 mutations and advanced breast cancer: A
proof-of-concept trial. Lancet, 376(9737): 235–244.
5. Farmer H, McCabe N, Lord CJ, et al., 2005, Targeting the
DNA repair defect in BRCA mutant cells as a therapeutic https://doi.org/10.1016/S0140-6736(10)60892-6
strategy. Nature, 434(7035): 917–921.
16. Gelmon KA, Tischkowitz M, Mackay H, et al., 2011,
https://doi.org/10.1038/nature03445 Olaparib in patients with recurrent high-grade serous or
6. Bryant HE, Schultz N, Thomas HD, et al., 2005, Specific poorly differentiated ovarian carcinoma or triple-negative
killing of BRCA2-deficient tumours with inhibitors of breast cancer: A phase 2, multicentre, open-label, non-
poly(ADP-ribose) polymerase. Nature, 434(7035): 913–917. randomised study. Lancet Oncol, 12(9): 852–861.
https://doi.org/10.1038/nature03443 https://doi.org/10.1016/S1470-2045(11)70214-5
7. Menear KA, Adcock C, Boulter R, et al., 2008, 17. Larraneta E, Lutton REM, Woolfson AD, et al., 2016,
4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4- Microneedle arrays as transdermal and intradermal drug
fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable delivery systems: Materials science, manufacture and
inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem, commercial development. Mat Sci Eng R, 104(June): 1–32.
51(20): 6581–6591. https://doi.org/10.1016/j.mser.2016.03.001
https://doi.org/10.1021/jm8001263 18. Pearton M, Saller V, Coulman SA, et al., 2012, Microneedle
8. Moynahan ME, Jasin M, 2010, Mitotic homologous delivery of plasmid DNA to living human skin: Formulation
recombination maintains genomic stability and suppresses coating, skin insertion and gene expression. J Control
tumorigenesis. Nat Rev Mol Cell Biol, 11(3): 196–207. Release, 160(3): 561–569.
https://doi.org/10.1038/nrm2851 https://doi.org/10.1016/j.jconrel.2012.04.005
9. Kim D, Nam HJ, 2022, PARP inhibitors: Clinical limitations 19. Zhao X, Coulman SA, Hanna SJ, et al., 2017, Formulation
and recent attempts to overcome them. Int J Mol Sci, of hydrophobic peptides for skin delivery via coated
23(15). microneedles. J Control Release, 265(November): 2–13.
https://doi.org/10.3390/ijms23158412 https://doi.org/10.1016/j.jconrel.2017.03.015

Volume 9 Issue 6 (2023) 37 https://doi.org/10.36922/ijb.0048